ĐẶC ĐIỂM SỬ DỤNG THUỐC ỨC CHẾ MIỄN DỊCH SAU GHÉP VÀ MỐI LIÊN QUAN ĐẾN ĐÁI THÁO ĐƯỜNG SAU GHÉP THẬN

Abstract

Objectives: To analyze the use of immunosuppressant drugs and the association with new-onset diabetes after renal transplantation (NODAT) in subjects three months post-transplantation. Subjects and methods: Including 508 patients with kidney post-transplant more than three months who are followed up and treated at Viet Duc University Hospital from September 2017 to April 2018. All patients volunteered to participate in the study. Collect blood samples of recipients in the morning before eating and taking immunosuppressants. Patients were diagnosed with new-onset diabetes after renal transplantation based on the American Diabetes Association (ADA). All patients received an anti-rejection regimen according to the procedure of Vietnam's Ministry of Health. Results:  The ratio of using immunosuppressive drugs from high to low order as follows: MMF/MPA (92.32%); prednisolone (91.54%); tacrolimus (81, .50%); basiliximab (75.59%); cyclosporin A (17.72%); everolimus (6.10%). Most of the patients using these drugs did not show the difference of rate between developing NODAT and non-NODAT; Only in patients using corticosteroids, the rate of patients with NODAT was 12.47% non-NODAT accounted for 87.53%, the difference was statistically significant with p <0.001. Conclusion: Modifying an immunosuppressant regimen, especially corticoid, may alter the risk of developing diabetes after kidney transplantation.